{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:19:14Z","timestamp":1781212754615,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T00:00:00Z","timestamp":1554768000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T00:00:00Z","timestamp":1554768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s13760-019-01138-y","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T11:03:15Z","timestamp":1554807795000},"page":"1333-1339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Multidisciplinary approach to Fabry disease: from the eye of a neurologist"],"prefix":"10.1007","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-055X","authenticated-orcid":false,"given":"Rah\u015fan","family":"\u0130nan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6104-2058","authenticated-orcid":false,"given":"Meral","family":"Me\u015fe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4740-2333","authenticated-orcid":false,"given":"Zerrin","family":"Bicik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,9]]},"reference":[{"key":"1138_CR1","first-page":"3733","volume-title":"The metabolic and molecula rbases of inherited disease","author":"RJ Desnick","year":"2014","unstructured":"Desnick RJ, Ioannou YA, Eng CM (2014) \u03b1-Galactosidase a deficiency: Fabry disease. In: Vogelstein B (ed) The metabolic and molecula rbases of inherited disease, 8th edn. TheMcGraw-Hill Companies, NewYork, pp 3733\u20133774","edition":"8"},{"issue":"8","key":"1138_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jmg.2008.065904","volume":"46","author":"A Mehta","year":"2009","unstructured":"Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, Sunder-Plassmann G, FOS Investigators (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS\u2014Fabry outcome survey. J Med Genet 46(8):548\u2013552","journal-title":"J Med Genet"},{"issue":"2","key":"1138_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10545-017-0098-3","volume":"41","author":"AB Burlina","year":"2018","unstructured":"Burlina AB, Polo G, Salviati L, Duro G, Zizzo C, Dardis A, Bembi B, Cazzorla C, Rubert L, Zordan R, Desnick RJ, Burlina AP (2018) Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy. J Inherit Metab Dis 41(2):209\u2013219. \n                  https:\/\/doi.org\/10.1007\/s10545-017-0098-3\n                  \n                (Epub 2017 Nov 15)","journal-title":"J Inherit Metab Dis"},{"key":"1138_CR4","volume-title":"Fabry disease: perspectives from 5 years of FOS","author":"B Winchester","year":"2006","unstructured":"Winchester B, Young E (2006) Biochemical and genetic diagnosis of Fabry disease, chapter 18. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford"},{"issue":"2","key":"1138_CR5","first-page":"157","volume":"81","author":"RJ Desnick","year":"1973","unstructured":"Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Krivit W (1973) Fabry\u2019s disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, andleukocytes. J Lab Clin Med 81(2):157\u2013171","journal-title":"J Lab Clin Med"},{"issue":"2","key":"1138_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1051\/jbio\/2002196020161","volume":"196","author":"DP Germain","year":"2002","unstructured":"Germain DP (2002) Fabry\u2019s disease (alpha-galactosidase-A deficiency): physiopathology, clinical signs, and genetic aspects. J Soc Biol 196(2):161\u2013173","journal-title":"J Soc Biol"},{"key":"1138_CR7","volume-title":"Fabry disease: perspectives from 5 years of FOS","author":"PB Deegan","year":"2006","unstructured":"Deegan PB, B\u00e4hner F, Barba M, Hughes DA, Beck M (2006) Fabry disease in females: clinical characteristics and effects of enzyme replacement therapy, chapter 30. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford"},{"issue":"1\u20133","key":"1138_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0014-2999(01)01312-7","volume":"429","author":"J MacDermot","year":"2001","unstructured":"MacDermot J, MacDermot KD (2001) Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur J Pharmacol 429(1\u20133):121\u2013125","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"1138_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/bjo.2006.100602","volume":"91","author":"A Sodi","year":"2007","unstructured":"Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S (2007) Ocular manifestations of Fabry\u2019s disease: data from the Fabry outcome survey. Br J Ophthalmol 91(2):210\u2013214","journal-title":"Br J Ophthalmol"},{"key":"1138_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eux261","author":"S Baig","year":"2017","unstructured":"Baig S, Edward NC, Kotecha D et al (2017) Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice. Europace. \n                  https:\/\/doi.org\/10.1093\/europace\/eux261\n                  \n                (Epub ahead of print)","journal-title":"Europace"},{"issue":"6","key":"1138_CR11","first-page":"549","volume":"45","author":"M Kay\u0131k\u00e7\u0131o\u011flu","year":"2017","unstructured":"Kay\u0131k\u00e7\u0131o\u011flu M, \u015eim\u015fek E, Kalkan U\u00e7ar S, Bayraktaro\u011flu S, Onay H, S\u00f6zmen E, \u00c7oker M (2017) Fabry disease: an overlooked diagnosis in adult cardiac patients. Turk Kardiyol Dern Ars 45(6):549\u2013555","journal-title":"Turk Kardiyol Dern Ars"},{"issue":"1\u20132","key":"1138_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jns.2014.06.029","volume":"344","author":"R El-Abassi","year":"2014","unstructured":"El-Abassi R, Singhal D, England JD (2014) Fabry\u2019s disease. J Neurol Sci 344(1\u20132):5\u201319. \n                  https:\/\/doi.org\/10.1016\/j.jns.2014.06.029","journal-title":"J Neurol Sci"},{"issue":"4","key":"1138_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/jmg.2005.036327","volume":"43","author":"PB Deegan","year":"2006","unstructured":"Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M, European FOS Investigators (2006) Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 43(4):347\u2013352","journal-title":"J Med Genet"},{"key":"1138_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13023-015-0296-8","volume":"10","author":"M Arends","year":"2015","unstructured":"Arends M, Hollak CE, Biegstraaten M (2015) Quality of life in patients with Fabry disease: a systematic review of the literature. Orphanet J Rare Dis 10:77","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1138_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR et al (2001) International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease. N Engl J Med. 345(1):9\u201316","journal-title":"N Engl J Med."},{"key":"1138_CR16","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743\u20132749","journal-title":"JAMA"},{"issue":"2","key":"1138_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/hrt.2006.104026","volume":"94","author":"DA Hughes","year":"2008","unstructured":"Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94(2):153\u2013158","journal-title":"Heart"},{"issue":"2","key":"1138_CR18","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","volume":"91","author":"R Schiffmann","year":"2017","unstructured":"Schiffmann R, Hughes DA, Linthorst GE, Ortiz A, Svarstad E, Warnock DG, West ML, Wanner C (2017) Conference participants. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference. Kidney Int 91(2):284\u2013293. \n                  https:\/\/doi.org\/10.1016\/j.kint.2016.10.004","journal-title":"Kidney Int"},{"key":"1138_CR19","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP et al (2016) Treatment of Fabry disease with the pharmacological chaperone migalastat. N Engl J Med 375:545\u2013555","journal-title":"N Engl J Med"},{"issue":"6","key":"1138_CR20","first-page":"422","volume":"55","author":"DA Hughes","year":"2018","unstructured":"Hughes DA, Nicholls K, Shankar SP, Sunder- Plassmann G, Koeller D, Nedd K, Vockley G, Hamazaki T et al (2018) Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet 55(6):422\u2013429","journal-title":"J Med Genet"},{"issue":"5","key":"1138_CR21","first-page":"406","volume":"9","author":"E Senocak Tasci","year":"2015","unstructured":"Senocak Tasci E, Bicik Z (2015) Safe and successful treatment with agalsidase beta during pregnancy in Fabry disease. Iran J Kidney Dis 9(5):406\u2013408","journal-title":"Iran J Kidney Dis"},{"key":"1138_CR22","volume-title":"Fabry disease: perspectives from 5 years of FOS","author":"R Schiffmann","year":"2006","unstructured":"Schiffmann R, Moore DF (2006) Neurological manifestations of Fabry disease, chapter 22. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford"},{"issue":"6","key":"1138_CR23","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.clinph.2008.02.004","volume":"119","author":"SM Laaksonen","year":"2008","unstructured":"Laaksonen SM, R\u00f6ytt\u00e4 M, J\u00e4\u00e4skel\u00e4inen SK, Kantola I, Penttinen M, Falck B (2008) Neuropathic symptoms and findings in women with Fabry disease. Clin Neurophysiol 119(6):1365\u20131372","journal-title":"Clin Neurophysiol"},{"key":"1138_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ymgme.2012.03.010","volume":"106","author":"M Biegstraaten","year":"2012","unstructured":"Biegstraaten M, Hollak CE, Bakkers M, Faber CG, Aerts JM, vanSchaik IN (2012) Small fiber neuropathy in Fabry disease. Mol Genet Metab 106:135\u2013141","journal-title":"Mol Genet Metab"},{"key":"1138_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/mus.880040506","volume":"4","author":"JF Pellissier","year":"1981","unstructured":"Pellissier JF, Van Hoof F, Bourdet-Bonerandi D, Monier-Faugere MC, Toga M (1981) Morphological and biochemical changes in muscle and peripheral nerve in Fabry\u2019sdisease. Muscle Nerve 4:381\u2013387","journal-title":"Muscle Nerve"},{"issue":"7","key":"1138_CR26","doi-asserted-by":"publisher","first-page":"e0180581","DOI":"10.1371\/journal.pone.0180581","volume":"12","author":"R Liguori","year":"2017","unstructured":"Liguori R, Incensi A, de Pasqua S et al (2017) Skin globotriaosylceramide 3 deposits are specific to Fabry disease with classical mutations and associated with small fibre neuropathy. PLoS ONE 12(7):e0180581","journal-title":"PLoS ONE"},{"key":"1138_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1744806916663729","volume":"12","author":"J Lakom\u00e1","year":"2016","unstructured":"Lakom\u00e1 J, Rimondini R, FerrerMontiel A, Donadio V, Liguori R, Caprini M (2016) Increased expression of Trpv1 in peripheral terminals mediates thermal nociception in Fabry disease mouse model. Mol Pain 12:1\u201316","journal-title":"Mol Pain"},{"issue":"10","key":"1138_CR28","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3389\/fnmol.2017.00449","volume":"25","author":"KK Kummer","year":"2018","unstructured":"Kummer KK, Kalpachidou T, Kress M, Langeslag M (2018) Signatures of altered gene expression in dorsal root ganglia of a Fabry disease mouse model. Front Mol Neurosci 25(10):449","journal-title":"Front Mol Neurosci"},{"issue":"7","key":"1138_CR29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/j.1445-5994.2007.01366.x","volume":"37","author":"M Low","year":"2007","unstructured":"Low M, Nicholls K, Tubridy N et al (2007) Neurology of Fabry disease. Intern Med J 37(7):436\u2013447","journal-title":"Intern Med J"},{"issue":"6","key":"1138_CR30","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/00004691-200212000-00011","volume":"19","author":"M D\u00fctsch","year":"2002","unstructured":"D\u00fctsch M, Marthol H, Stemper B, Brys M, Haendl T, Hilz MJ (2002) Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol 19(6):575\u2013586","journal-title":"J Clin Neurophysiol"},{"key":"1138_CR31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/mus.10181","volume":"26","author":"D Lacomis","year":"2002","unstructured":"Lacomis D (2002) Small-fiber neuropathy. Muscle Nerve 26:173\u2013188","journal-title":"Muscle Nerve"},{"issue":"12","key":"1138_CR32","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(17)30377-0","volume":"16","author":"AJ Terkelsen","year":"2017","unstructured":"Terkelsen AJ, Karlsson P, Lauria G, Freeman R, Finnerup NB, Jensen TS (2017) The diagnostic challenge of small fibre neuropathy: clinical presentations, evaluations, and causes. Lancet Neurol 16(12):954","journal-title":"Lancet Neurol"},{"issue":"3","key":"1138_CR33","doi-asserted-by":"publisher","first-page":"258","DOI":"10.5152\/npa.2015.7646","volume":"52","author":"\u00c7K Akpinar","year":"2015","unstructured":"Akpinar \u00c7K, T\u00fcrker H, Bayrak O, Cengiz N (2015) Electroneuromyographic features in Fabry disease: a retrospective review. Noro Psikiyatr Ars 52(3):258\u2013262","journal-title":"Noro Psikiyatr Ars"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-019-01138-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13760-019-01138-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-019-01138-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T18:12:16Z","timestamp":1604772736000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13760-019-01138-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,9]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1138"],"URL":"https:\/\/doi.org\/10.1007\/s13760-019-01138-y","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,9]]},"assertion":[{"value":"22 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}